Tag: Regulatory

CHARLOTTE, N.C., June 25, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Greenland Mines" or the "Company") (Nasdaq: GRML) is pleased to announce that it has...

Project delivered under a US$41 million transaction as part of the 21 MW DC Honeywell portfolio in upstate New York7.01 MW DC ground-mount solar...

Beam Global is relocating manufacturing from San Diego to Yuma, Arizona, reducing costs, improving margins, and supporting future growth.

Herbalife–IIT Madras Centre of Excellence aims to position India as a global leader in sustainable biomanufacturing and next-generation plant-derived health and wellness productsCHENNAI, India,...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Bringing together Elektrobit's software platform and AUTOCRYPT's cybersecurity engineering expertise Advancing software-defined mobility innovation through strategic collaboration SEOUL, South Korea, June 25, 2026 /PRNewswire/ -- AUTOCRYPT, a leading...

CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Global market projected to grow at a CAGR of 13.5% from 2026 to 2033 as pharmaceutical, food, and healthcare industries increasingly rely on advanced...

Hosted free by Pharmacy Stars on June 25, eight Camino Compass faculty, led by Principal Faculty Jocelyn Freimuth, PharmD, MBA, BCSCP, will put 64...